Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 1/20 | 0.51 |
| ▸ | JMJD6 | Q6NYC1 | 5/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | SLC11A2 | P49281 | 1/20 | 0.35 |
| ▸ | PROKR1 | Q8TCW9 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | CCR3 | P51677 | 1/20 | 0.34 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4792240 | 0.90 | PIK3CA (0.43) | PIK3CAPROKR1DPP4 | |
| SCHEMBL4879470 | 0.79 | OGA (0.42) | HRH3ALDH1A1MAPK1MAPTHTT | |
| SCHEMBL6949764 | 0.75 | PIK3CA (0.70) | PIK3CAJMJD6HRH3ALDH1A1MAPK1 | |
| SCHEMBL15121873 | 0.71 | PIK3CA (0.46) | PIK3CA | |
| SCHEMBL1516956 | 0.70 | PIK3CA (0.75) | PIK3CAJMJD6ALDH1A1MAPK1KDM4E | |
| SCHEMBL15121683 | 0.69 | ABCC2 (0.57) | — | |
| SCHEMBL7078995 | 0.66 | PIK3CA (0.59) | PIK3CAJMJD6HRH3ALDH1A1MAPK1 | |
| SCHEMBL15121747 | 0.66 | PIK3CA (0.46) | PIK3CAJMJD6HRH3ALDH1A1P2RY12 | |
| SCHEMBL25386009 | 0.66 | CHIA (0.73) | — | |
| SCHEMBL17263330 | 0.66 | PIK3CA (0.61) | PIK3CAJMJD6ALDH1A1MAPK1SLC11A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312211-A1 | Antibacterial Pyrrolopyridines, Pyrrolopyrimidines and Pyrroloazepines-154 | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | claimed |
| US-20080312211-A1 | Antibacterial Pyrrolopyridines, Pyrrolopyrimidines and Pyrroloazepines-154 | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312211-A1 | Antibacterial Pyrrolopyridines, Pyrrolopyrimidines and Pyrroloazepines-154 | SDHA, QDPR, PNKP | PIK3CA 494/4885JMJD6 3317/4885HRH3 3006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.